Sidhaant Life Sciences Private Limited

Sidhaant Life Sciences Private Limited, incorporated on October 1, 2004, is a private limited company based in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U51397DL2004PTC129632. Its authorized capital stands at ₹10 million, with a paid-up capital of ₹7.65 million. The registered office is located at 808 8th Floor, Vishal Tower, District Centre, Janakpuri, New Delhi, 110058.

Sidhaant Life Sciences specializes in the wholesale and retail trade of pharmaceutical products, including tablets, capsules, syrups, and injections. The company has a workforce of approximately 12 employees as of April 8, 2024. Financially, the company reported a 24.8% decrease in total revenue for the fiscal year 2023, with a net profit decline of 69.49%.

Sidhaant Life Sciences operates manufacturing facilities in New Delhi and Gurugram, Haryana. The New Delhi facility is situated at 808 8th Floor, Vishal Tower, District Centre, Janakuri, New Delhi, 110058. The Gurugram facility is located at Basement, Ground, and First Floor, Plot-459, Phase III, Udyog Vihar, Gurugram, Haryana, 122008. Specific details regarding production capacities and specializations are not publicly disclosed.

The board of directors at Sidhaant Life Sciences comprises:

• Sudarshan Sabharwal
• Jetender Sabharwal
• Sulabh Nayar
• Anu Nayar
• Sidhaant Sabharwal

These individuals have been associated with the company since its inception on October 1, 2004. Detailed information regarding their specific roles and professional backgrounds is not publicly available.

Sidhaant Life Sciences has engaged in exporting pharmaceutical formulations to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals from the Directorate General of Foreign Trade (DGFT) for these exports. However, specific details regarding approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA), and Pharmaceuticals and Medical Devices Agency (PMDA) are not publicly disclosed.

Sidhaant Life Sciences has expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's export activities in these regions are facilitated by obtaining export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT). Specific details regarding WHO prequalification or other certifications enabling market access are not publicly available.

Sidhaant Life Sciences has diversified its export portfolio across multiple therapeutic categories, including nutritional supplements, antimalarial and antiparasitic agents, and antibiotics. This diversification strategy mitigates concentration risk and positions the company to leverage opportunities in various global markets. The company's strategic direction focuses on expanding its international footprint while maintaining a balanced product portfolio.

Specific information regarding Sidhaant Life Sciences' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company has engaged in exporting pharmaceutical formulations to the United States; however, detailed regulatory approval statuses are not disclosed.

Sidhaant Life Sciences has obtained Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU). These certifications are essential for exporting pharmaceutical products to international markets. Specific details regarding the scope and validity of these certifications are not publicly disclosed.

The company holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained state drug controller approvals for its facilities. Additionally, Sidhaant Life Sciences has secured export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export activities. Specific details regarding the validity and scope of these approvals are not publicly available.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Sidhaant Life Sciences by regulatory authorities. The company maintains a compliant status with regulatory bodies, ensuring the quality and safety of its pharmaceutical products.

Sidhaant Life Sciences operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly disclosed, the company's diversified product portfolio and international presence position it as a notable competitor in the industry. The company's focus on quality manufacturing and adherence to international standards enhances its competitive edge.

Sidhaant Life Sciences' key differentiators include its diversified product portfolio across multiple therapeutic categories, adherence to international quality standards, and a strategic focus on expanding its international market presence. These factors contribute to the company's ability to meet diverse customer needs and maintain a competitive position in the global pharmaceutical export market.

Sidhaant Life Sciences is strategically positioned as a pharmaceutical exporter with a focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's future outlook involves expanding its international footprint, enhancing product offerings, and maintaining compliance with global regulatory standards to meet the evolving demands of the pharmaceutical industry.

Sidhaant Life Sciences has a track record of consistent export activities, with a total export value of $3.0 million USD across 63 shipments from 2022 to 2026. The company's portfolio includes four products across four therapeutic categories, with the top five products contributing to 100% of the export value. This indicates a focused approach to its export strategy, emphasizing quality and specialization.

Importers should verify the following certifications when considering products from Sidhaant Life Sciences:

• FDA Approval: Confirm the FDA registration status of the manufacturing facility and the approval of specific products.

• WHO-GMP Certification: Ensure the manufacturing facility holds valid WHO-GMP certification, indicating compliance with international quality standards.

• EU GMP Certification: Verify the validity of EU GMP certification for the manufacturing facility, ensuring adherence to European Union quality standards.

• ISO Certification: Check for ISO certifications related to quality management systems, such as ISO 9001, to assess the company's commitment to quality.

To verify these certifications, importers can request copies of the certificates from Sidhaant Life Sciences and cross-reference them with the issuing authorities' official records.

When conducting due diligence on Sidhaant Life Sciences, importers should consider the following steps:

• Verify Regulatory Approvals: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Financial Health: Review the company's financial statements for the past three years to evaluate profitability and financial stability.

• Evaluate Product Quality: Request product samples and conduct quality assessments to ensure compliance with international standards.

• Check Export History: Review the company's export records to assess consistency and reliability in fulfilling international orders.

• Inspect Manufacturing Facilities: If possible, conduct site visits to the manufacturing facilities to assess compliance with quality standards and regulatory requirements.

Red flags to watch for include discrepancies in certification documents, irregularities in financial records, and a lack of transparency in manufacturing processes. Recommended pre-order checks involve verifying the authenticity of certifications, assessing the company's reputation in the industry, and ensuring clear communication regarding product specifications and delivery timelines.